Valbiotis Launches €10.2M Capital Increase with Strong Commitments

Valbiotis, a French laboratory specializing in scientifically tested nutritional solutions, has announced a capital increase of €10.2 million. This initiative, retaining preferential subscription rights (PSR), is bolstered by 76.6% commitment assurance. The funding is anchored by a €2 million commitment from Tao Xianhua, Aika's Co-Founder, and €5.8 million in guarantee commitments.

The subscription price is set at €0.86 per share, a 19.9% discount from recent trading sessions. The PSR detachment begins on June 10, and the trading period runs until June 22, with the subscription window open from June 12 to 24.

Valbiotis aims to utilize these funds primarily to boost its commercial development. CEO Sébastien Peltier emphasized the company's growth, noting significant progress in pharmacy networks and e-commerce, as well as international expansion plans in Asia and the Middle East.